Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to ...
Complete SAD/MAD data from the Phase 1 trial of DISC-3405 in healthy volunteers were presented. In the SAD portion of this trial, healthy males and females ages 18 to 65 were given a single dose of ...
SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
Thalassemia is a condition in which the body makes less hemoglobin, a protein that's an important part of red blood cells. This results in red blood cells being destroyed, which is known as hemolytic ...
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
The treatment CS-101 uses innovative transformer Base Editing (tBE) technology to help people with severe diseases such as ...
The viruses that scare me are the ones I don’t know about.” Anthony Fauci, long-time director of the National Institute ...
Thalassemia is a rare inherited blood disorder caused by genetic mutations that lead to a reduced production of healthy hemoglobin, compromising red blood cell development, health and survival, and ...